jadenu 180 mg film-coated tablet film-coated tablet
novartis pharma schweiz ag, switzerland - deferasirox - film-coated tablet - 180 mg
jadenu 360 mg film-coated tablet film-coated tablet
novartis pharma schweiz ag, switzerland - deferasirox - film-coated tablet - 360 mg
piqray film-coated tablet
novartis pharma schweiz ag, switzerland - alpelisib - film-coated tablet - 200 mg
piqray film-coated tablet
novartis pharma schweiz ag, switzerland - alpelisib - film-coated tablet - 150 mg
piqray 200 mg + 50 mg film-coated tablet
novartis pharma schweiz ag, switzerland - alpelisib - film-coated tablet - 250 mg,
kesimpta solution for injection in pre-filled pen
novartis pharma schweiz ag, switzerland - ofatumumab - solution for injection in pre-filled pen - 20 mg/ml
jadenu 90 mg film-coated tablet film-coated tablet
novartis pharma schweiz ag, switzerland - deferasirox - film-coated tablet - 90 mg
jadenu 180 mg film-coated tablet film-coated tablet
novartis pharma schweiz ag, switzerland - deferasirox - film-coated tablet - 180 mg
jadenu 360 mg film-coated tablet film-coated tablet
novartis pharma schweiz ag, switzerland - deferasirox - film-coated tablet - 360 mg
cosentyx solution for injection
novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy